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Toll like receptorsa b s t r a c t
Toll-like receptors (TLRs) mediate interactions between environmental stimuli and innate immunity.
TLRs play a major role in the development of numerous pancreatic diseases, making these molecules
attractive as potential therapeutic targets. TLR2, TLR7 and TLR9 are involved in the initiation of type 1
diabetes mellitus (T1DM), whereas TLR2 and TLR4 play a major role in the onset of type 2 diabetes
mellitus (T2DM). Furthermore, TLRs cause derangements in several tumor suppressor proteins (such as
p16, p21, p27, p53 and pRb), induce STAT3 activation and promote epithelial–mesenchymal transition
as well as oncogene-induced senescence. In this review we will focus on the contribution of TLRs in pan-
creatic disease including cancer and we describe recent progress in TLR-modulation for the treatment of
these patients.
 2015 Elsevier Ltd. All rights reserved.Introduction tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF-6)Activation of innate immunity is achieved through the stimula-
tion of pattern recognition receptors (PRRs). Among them, Toll-like
receptors (TLRs) were the ﬁrst group to be identiﬁed. They can be
activated by a panel of pathogen-associated molecular patterns
(PAMPs) [1,2] and alarmins [3] endogenous molecules released
by activated or necrotic cells in response to stress or tissue damage
into the extracellular compartment [4].
Another feature of PPRs is their capability to recognize
self-molecular patterns originated from damaged cells, named
Damage Associated Molecular Patterns (DAMPs).
TLRs are single-pass transmembrane proteins with an intracel-
lular C-terminal tail known as the Toll/IL-1 receptor (TIR) and an
extracellular N-terminal that contains leucine-rich repeats (LRRs).
TLR ligation leads to activation of two major intracellular signaling
pathways. All TLRs, except TLR3, can activate a Myeloid differenti-
ation primary response protein 88 (MyD88)-dependent pathway
(Fig. 1). This pathway involves IL-1R-associated kinases (IRAK),and mitogen-activated kinases and leads to the transcription of
pro-inﬂammatory genes through the activation of nuclear factor
jb (NFjB) and/or the activation of activating protein 1 [5,6].
Furthermore, TLR3 and TLR4 can activate the TIRAP inducing inter-
feron b (TRIF) pathway, leading to the synthesis of interferon-a/b
(IFN-a/b) [5].
At present, twelve TLRs have been identiﬁed in mice (TLR1–
TLR9 and TLR11–TLR13) and ten in human (TLR1–TLR10) [3].
Most TLRs are on the cell surface, except for TLR3, -7, -8, and -9,
mainly present in the endosomes [2]. A further classiﬁcation
divides TLRs based on the type of recognized PAMPs: TLR1, TLR2,
TLR4 and TLR6 detect lipids, whereas TLR5 and TLR 10 recognize
proteins and TLR3, TLR7, TLR8 and TLR9 detect nucleic acids [5].
The list of PAMPs and alarmins recognized by human TLRs is
shown in Table 1.
The involvement of TLRs in the pathophysiology of several
diseases has become a major research ﬁeld [6,7]. This review
summarizes the role of TLRs in the pathogenesis of inﬂammatory
related pancreatic disease as well of pancreatic cancer, highlighting
their potential use as future therapeutic targets.
Methods
Data for this review were identiﬁed from the Pubmed database,
using the subsequent MeSH (Medical Subject Heading) terms:target.
Fig. 1. TLR signaling pathways. All TLRs except TLR3 can activate a Myeloid differentiation primary response protein 88 (MyD88)-dependent pathway. TLR2 and TLR4 also
recruit a MyD88-like adaptor molecule Mal, thus activating NF-jB through an IkB kinase (IKK) complex. NF-jB then translocate to the nucleus where it binds to jB promoter
elements resulting in the expression of inﬂammatory cytokines, such as TNF-a, IL-1 and IL-6. TLR3 via the TIR-domain containing-adaptor inducing interferon-b (TRIF) leads
to the activation of interferon regulatory factor (IRF) 3. IRF3 dimerises and translocates into the nucleus and binds to interferon-sensitive response element (ISRE) motifs, thus
promoting the expression of interferon (IFN)-a/b. TLR4 can also utilize the TRIF-related adaptor molecule (TRAM) for the activation of NF-jB and IRF3. On the other hand,
TLR7 and TLR9 can also activate IRF3 related molecules such as IRF7, leading to the expression of IFN-a/b.
Table 1
Ligand recognition by Toll-like receptors.
TLRs Localization PAMP Origin of PAMP
TLR1 Plasma membrane Triacyl lipopeptides N. meningitidis triacyl lipopeptides bacteria, mycobacteria
TLR2 Plasma membrane Glycoinositolphospholipids, glycolipids,
haemagglutinin, lipoarabinomannan, lipoprotein/
LIPOPEPTIDES, lipoteichoic acid, zymosan,
peptidoglycan, phenol-soluble modulin, porins
Trypanosoma cruzi, Treponema maltophilum, virus, mycobacteria,
various pathogens, gram-positive bacteria, gram-positive bacteria,
S. epidermidis, neisseria, fungi
TLR3 Endosome Double-stranded RNA Virus
TLR4 Plasma membrane Envelope protein, fusion protein, heat-shock
protein 60, lipopolysaccharide, taxol
Mouse-mammary tumor virus, respiratory syncytial virus,
Chlamydia pneumoniae, gram-negative bacteria, plants,
TLR5 Plasma membrane Flagellin Bacteria
TLR6 Plasma membrane Diacyl lipopeptides, zymosan, lipoteichoic acid Mycoplasma, gram-positive bacteria, fungi
TLR7 Endosome Single-stranded RNA Virus
TLR8 Endosome Single-stranded RNA Virus
TLR9 Endosome DNA (CpG), haemozoin Bacteria, virus, Plasmodium spp., Rhodnius spp., Schistosoma spp.
TLR10 Endosome Not determined Not determined
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Role of TLRs in acute pancreatitis
Acute pancreatitis (AP) is characterized by early activation of
intracellular proteases followed by acinar cell death and inﬂamma-
tion. Mild acute pancreatitis (MAP), also known as edematous
acute pancreatitis represents 80% of AP. While patients with MAP
commonly recover without complication since MAP is a
self-limited disease, in severe acute pancreatitis (SAP) (20%) there
are frequent local and extrapancreatic complications inducing
systemic inﬂammatory response syndrome (SIRS) and sequential
multiple organ disfunction syndrome (MODS) [8].
Acinar and fat cells are the early cells damaged in AP, causing
disregulation in basolateral secretion and enhanced ductal perme-
ability. This event leads to early plasmatic increase of clinical
markers of pancreatic injury, such as lipase and amylase [9]. The
intracellular protective mechanisms that prevent enzymes activa-
tion include synthesis of trypsin as inactive enzyme trypsinogen,
autolysis of activated trypsin, enzyme compartmentalization,
synthesis of speciﬁc trypsin inhibitors such as serine proteaseFig. 2. The sterile inﬂammatory response in acute pancreatitis. Sterile stimuli that
intracellular cytokines released from necrotic cells can activate the host immune s
1 = interleukin-1; IL-1R = IL-1 receptor; NLRP3 = NOD-, LRR- and pyrin domain-containin
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A wider enzymatic activation, involving elastase phospholipase
A2, complement and kinin pathways, occurs after tripsinogen
activation into trypsin in acinar cells. These events cause gland
autodigestion, local inﬂammation and lastly the release of intracel-
lular contents from necrotic cells. The transendothelial migration
of leucocytes ampliﬁes the tissue damage, due to the release of
leucocyte harmful enzymes, the generation of oxygen-derived free
radicals and the increase of pancreas hypoxia caused by vessel
damages, amplifying the pro-inﬂammatory condition [8].
In health conditions, DAMPs are sequestered inside the cell, but
after tissues injury, they are released in the extracellular space
becoming available to cell surface PRRs. Since DAMPs engage the
same PRRs as microbial agents, their inﬂammatory state has been
indicated as ‘‘sterile inﬂammation’’ (Fig. 2) [9]. This status involves
TLRs (TLR4 or TLR9) and the signaling launched by the membrane
purigenic receptor P2X and intracellular NOD-like receptors (NLR),
which leads to the activation of Caspase 1, a cytosolic cystein pro-
tease that regulates the conversion of pro-cytokines into mature
forms [9]. A number of DAMPS (such as high-mobility group box
protein 1 (HMGB1), adenosine triphosphate and heat shock proteininclude damage-associated molecular patterns (DAMPs), sterile particulates and
ystem to induce sterile inﬂammation. HMGB1 = high-mobility group box 1; IL-
g 3; RAGE = receptor for advanced glycation end-products; TLR = toll like receptor.
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HMGB1 is released by injured acinar cells and acts as a proinﬂam-
matory cytokine with neoangiogenetic and chemotactic activity. It
affects cell proliferation and regeneration of damaged tissues
stimulating autophagy [10]. Furthermore, HMGB1 activates sterile
inﬂammation through TLR, especially TLR4. TLR4 is expressed not
only on immune system cells, but also in pancreatic ductal and
endothelial cells or in tissue macrophages (thus called
DAMP-sensing cells). Notably, TLR4 is not expressed in acinar cells
[9]. In mice with caerulein-induced pancreatitis (CIP), TLR4 deﬁ-
ciency is associated with a delayed development of pancreatitis
[11]. Similarly, other reports show that acinar cell necrosis, edema
and hemorrhage induced by taurocholate are signiﬁcantly
decreased in TLR4-deﬁcient mice [12].
TLR9 is expressed in immune cells, pancreatic ductal and
endothelial cells, but not in acinar cells. TLR9 recognizes microbial
nucleic acid, speciﬁcally CpG motifs (unmethylated
cytosine-phosphate-guanine (CpG) dinucleotides in DNA
sequences). Host genomic DNA released by necrotic acinar cells
is elevated in serum as very early AP event and is recognized as
a DAMP by TLR9 promoting an immune activation of sterile
inﬂammation [9]. In addition, TLR9 induced by HMGB1 promotes
the formation of CpG-DNA-TLR9 complex. HMGB1 interacts and
preassociates with TLR9 in the endoplasmic reticulum–Golgi inter-
mediate compartment (ERGIC), and hastens TLR9 redistribution to
early endosomes in response to CpG-DNA. Loss of HMGB1 leads to
a defect in response to CpG-DNA in terms of IL-6, IL-12, TNF-a, and
inducible nitric-oxide synthase expression [13]. Interestingly, the
genetic deletion of TLR9 in pancreatitis leads to reduced pancreatic
edema, inﬂammation, and pro-IL-1b expression [14].
Systemic inﬂammatory response syndrome (SIRS) in AP: role of TLRs
SIRS is a clinical condition characterized by a speciﬁc physiolog-
ical alteration of body temperature, white blood cell count, heart
and respiratory rates. SIRS and sepsis may be differentiated by
the presence or absence of a focus of infection. AP represents one
of the most common non-infectious causes of SIRS [15].
In AP, SIRS leads to distant organ damage, hypotension or
hypoperfusion and MODS, which is the primary cause of morbidity
and mortality in this condition.
TLRs have been shown to play a major role in the development
of SIRS. However, the recognition of PAMP by TLRs is not able to
explain the etiology of SIRS or the pathogenesis of such ‘‘sterile
conditions’’ as ischemia and atherosclerosis, where no infection
can be found. Zhai et al. reported that ischemic injury to the liver
does not occur in mutant mice hosting a non-functional TLR4,
and that the activation of TLR4 is not mediated by lipopolysaccha-
ride (LPS), the archetypic agonist for TLR4 [16]. In addition, theTable 2
Selection of agents under evaluation in the treatment of AP. IL: interleukin; MIF: migratio
Agent Description
WY14643 Peroxisome proliferator-activated receptor-a agonist
Chloroquine Weak base that accumulates in the lysosomes and increases th
L-Arg 2-Amino-5-guanidinopentanoic acid (amino acid)
IRS954 TLR9 antagonist
Emodin 1,3,8-trihydroxy-6-methylanthraquinone
Eritoran Structural inhibitor of the lipid A portion of LPS
TAK 242 Cyclohexene derivative
Danshen Dried root and rhizome of the medicinal plant
Salvia miltiorrhiza Bunge (Labiatae)
Anti-MIF antibody 20 lg/animal
Baicalin Flavonoid, prolyl endopeptidase inhibitor
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greatly diminished in TLR4-mutant mice [17].
A central role in the initiation, maintaining and progression of
AP to SIRS is played by pro-inﬂammatory mediators such as tumor
necrosis factor (TNF) and IL-1, IL-6, IL-8, IL-10, PAF, C5a and
ICAM-1 [18]. Their secretion and expression is closely regulated
by the activation of gene promoters through NF-jB, which is the
ending point of TLRs signaling pathway [19]. Moreover, TLR2 and
TLR4 seem to be involved in lung and liver injuries as complica-
tions of AP [20].
Therapeutic perspectives
Despite a lack of studies speciﬁcally evaluating the role of
TLR-modulation in the clinical setting of AP, there is a growing
body of evidence that both the TLRs and downstream TLR signaling
pathways may be promising therapeutic targets (Table 2).
Several agents have been proposed to modulate TLR4 activities.
Eritoran, is a structural inhibitor of the lipid A portion of LPS, has
been shown to inhibit TLR4 [21]. On the other hand, Resatorvid
(TAK 242) is a selective inhibitor of signaling from the intracellular
domain of TLR4 [22]. However, a non-signiﬁcant reduction in
mortality rate in patients with severe sepsis has been reported
[23,24]. Therefore, the potential use of TLR4 antagonists in patients
with AP or SIRS is still controversial.
TLR9 is important DAMP receptor upstream of inﬂammasome
activation, and its antagonism could provide a new therapeutic
strategy for treating AP. In 2011, Hoque et al. revealed that compo-
nents of the inﬂammasome (apoptosis-associated speck-like pro-
tein containing a caspase recruitment domain [ASC], NLRP3,
caspase-1), as well as TLR9, were essential for CIP development in
wild-type mice and mice deﬁcient in inﬂammasome components.
Pretreatment with IRS954 (TLR9 antagonist) reduced pancreatic
edema, inﬂammatory inﬁltrate, pancreatic necrosis and lung
inﬂammation in taurolithocholic acid 3-sulfate-induced AP [14].
The inhibition of HMBG1, by using of blocking antibodies,
decreases pancreatic injury and lung inﬂammation in an experi-
mental model of severe AP [25]. Similarly, pharmacologic antago-
nism of both TLR9 and TLR7 decreases acinar cell necrosis and
lung injury in an experimental model of severe AP [14].
Lysosomal acidiﬁcation is required for endosomal TLR-mediated
immune responses. Chloroquine, through the inhibition of endoso-
mal acidiﬁcation, has been shown to reduce pancreatic injury and
mortality in an experimental AP model [26].
Furthermore, the recombinant IL-1 receptor antagonist has
been shown to decrease pancreatic injury and inﬂammation [27].
Peroxisome proliferator-activated receptor-a (PPAR-a) has
attracted considerable attention for its anti-inﬂammatory proper-
ties. It has been reported that the administration of the PPAR-an inhibitory protein; TLR: Toll-like receptor; TNF-a = tumor necrosis factor-a.
Activity in AP
Markedly decreases TLR2 and TLR4 mRNA and proteins, along with
IL-6, ICAM-1 and TNF-a mRNA levels
eir pH Inhibit endosomal acidiﬁcation, required for some TLR activation
Down-regulates TLR2 and TLR4 and stimulates the production of nitric
oxide, meliorating lung and liver damages
Reduces pancreatic edema, inﬂammatory inﬁltrate, and apoptosis
Suppress TLR4 up-regulation
Inhibits TLR4 activity
Inhibits TLR4 signaling
Inhibits the binding of LPS to TLR4, reducing bacterial translocation
and liver injury
Suppress the AP-induced elevation of TLR-4 pulmonary expression
Suppress TLR4 up-regulation
creatic diseases: From a pathogenetic mechanism to a therapeutic target.
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myeloperoxidase activity, as well as IL-6, and ICAM-1 levels.
Moreover, the TLR2 and TLR4 mRNA and proteins were markedly
decreased by WY14643, along with IL-6, ICAM-1, and TNF-a
mRNA levels, suggesting for a potential use of WY14643 in AP
attenuation [28].Role of TLRs in diabetes mellitus and its complications
Diabetes is among the leading causes of death and disability
affecting more than 348 million people worldwide [29]. Its inci-
dence is rapidly increasing, and by 2030, this number is estimated
to almost double [30]. A growing body of evidence has indicated
that diabetes and its complications underlie a proinﬂammatory
state characterized by elevated plasma C-reactive protein, cytoki-
nes (IL-1, TNF-a, IL-6), chemokines, adhesion molecules, and
monocyte activity.
Furthermore, the activation of the innate immune system via
TLRs, TLR2 and TLR4 in particular, seems to play a key role in the
pathogenesis of both type 1 (T1DM) and type 2 diabetes mellitus
(T2DM).
While apoptosis of pancreatic b-cells, after a long sequence of
autoimmune processes, appears to be the last step in the develop-
ment of T1DM, the initial event in the pathogenesis of T1DM has
not been cleared, although several authors proposed the sensing
of DAMP from b-cells by TLR2 on dendritic cells (DCs) as the ﬁrst
event. An increase in receptors and mRNA expression of TLR2 and
TLR4 inmonocytes was reported from patients with T1DM, without
vascular complications, compared to healthy controls [31], as well
as an upregulation of downstream targets of TLR signaling includ-
ing MyD88, TRIF, phosphorylated IL-1 receptor-associated kinase,
and NF-jB. In addition, elevated TRL2 and TLR4 expressions are sig-
niﬁcantly associated with glycemic control and advanced glycation
end products. Knockdown of both TLR2 and TLR4 resulted in a 76%
decrease in high glucose-induced NF-jB response, suggesting an
addictive effect [32–34]. Kim et al. found that diabetogenic T cell
priming and the development of autoimmune diabetes were signif-
icantly inhibited in TLR2-null NOD mice. These data suggest that
TLR2 blockade could be used in the treatment of autoimmune dia-
betes [34]. Furthermore, Mohammad and colleagues showed that
TLR2 and TLR4 expression was increased in T1DM non-obese mice
and correlated with NF-jB activation in response to LPS. These
results were also conﬁrmed in a study in streptozotocin-induced
diabetic mouse models [35].
TLRs seem to be involved even in the pathogenesis of T2DM. An
increased mRNA expression of TLR2 and TLR4 in peripheral mono-
cytes and increased TLR2 expression only in subcutaneous adipose
tissue in T2DM was observed [36]. Moreover, an excess of glucose
and free fatty acid (FFA) induced elevated TLR2 and TLR4 mRNA
and protein expression in monocytes from patients with untreated
T2DM [37]. Similarly, TLR2 and TLR4 mediate FFA-induced activa-
tion of inﬂammatory pathways and metabolic signaling in insulin
resistance, mainly though NF-jB activation [38,39].
Adipose tissue appears to be a major site of production of
inﬂammatory mediators, as a result of the cross-talk between adi-
pose cells, macrophages, and other inﬁltrating immune cells. An
increased TLR2 expression has been demonstrated in subcutaneous
adipose tissue of patients with T2DM [40]. Similarly, an increased
TLR4 gene and protein expression was found in the muscle biopsies
from obese subjects and patients with T2DM compared to thin
subjects, along with an increase in NF-jB signaling and release of
IL-6 and TNF-a [41].
The activation of TLR4 induces inﬂammation in adipocytes in
human and murine models of T2DM [42,43]. A recent study
showed an increase in TLR-expressing B cells in patients withPlease cite this article in press as: Santoni M et al. Toll like receptors and pan
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observed in diabetic patients on treatment with anti-inﬂammatory
medications [44]. Notably, polymorphisms in the TLR3 gene seem
to be associated to the risk of T1DM. In fact, rs5743313 and
rs117221827 polymorphisms were associated with an early age
at diagnosis and a worse glycemic control [45]. While the presence
of TLR4 +3725G/C polymorphism seems to be a novel protective
factor against T2DM [46], the presence of a nonsense polymor-
phism (R392X) in TLR5 gene seems to protect from obesity and
to predispose to T2DM [47]. However, these results should be
investigated in prospective series. Of note, exercise, but not
diet-induced weight loss, can modulate the role of TLRs in diabetes
[48,49].
Most interestingly, several studies reported correlation
between TLR expression and developing of diabetic complications.
Experimental studies demonstrated that TLR2 and TLR4 could be
important participants in the progression of atherosclerosis in
diabetes [50,51].
Furthermore, TLR4 is upregulated in diabetic cardiomyocytes
and plays a role in regulating lipid accumulation in cardiac muscle
after the onset of type 1 diabetes, which may contribute to cardiac
dysfunction [52].
Therapeutic perspectives
An improved understanding of the mechanisms linking inﬂam-
mation to diabetes mellitus has stimulated interest in targeting
inﬂammatory pathways as a part of the strategy to prevent or to
control diabetes mellitus and its complications. However, the
current strategies to decrease inﬂammation in diabetes are
empirical and some of these include statins, which can reduce
TLR2 and TLR4 expression [53], PPAR-c agonists, angiotensin
receptor blockers (ARBs) and omega-3 fatty acids. In addition,
phytochemicals may be also employed, such as D vitamin [54],
orange juice [55] and citrus ﬂavonoid naringenin [56].
To date, there are no approved therapeutic agents targeting
TLRs for diabetes. Recently, the effects of immune tolerance,
induced by chronic administration of TLR2 agonist Pam3CSK4,
and Dipeptidyl peptidase 4 (DPP4) inhibitors have been investi-
gated. Diabetogenic T cell priming by DCs was attenuated by
chronic treatment with Pam3CSK4, indicating DC tolerance. The
association with DPP4 could achieve normoglycemia by TLR2
tolerization in combination with DPP4 inhibition but not by TLR2
tolerization or DPP4 inhibition alone [57]. In the same view, the
use of TLR9 antagonist oligodeoxynucleotide or chloroquine
inhibited bone marrow-derived DCs activation and CD8(+) T cell
priming in response to CpG, thus delaying the spontaneous onset
of diabetes in NOD mice [58].
At present, a phase II trial (NCT01151605) is ongoing to evalu-
ate the suppression of TLRs by insulin in lean, obese and T2DM
patients. Another study (NCT01740817) is running to determine
whether a lipid infusion can up-regulate TLR4 signaling in human
subjects with obesity and/or diabetes and an observational trial
(NCT01561664) is evaluating the regulation of inﬂammation in
obese patients by muscle and fat biopsy. Finally, a phase 4 study
(NCT01250340) is assessing the role of TLRs in the pathophysiol-
ogy of T2DM and associated atherosclerosis in patients treated
with aspirin or placebo.
In the last years, a major focus has been reserved to the rela-
tionship among exercise, inﬂammation and innate immunity. The
expression of TLR2 and TLR4 on human monocytes in vivo is mark-
edly reduced by strenuous exercise [59]. Moreover, it has been
reported that down-regulation of TLR2 and TLR4 expression was
associated with improved insulin sensitivity after diet-induced
weight loss in human subjects with abnormal glucose tolerance
and metabolic syndrome.creatic diseases: From a pathogenetic mechanism to a therapeutic target.
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Pancreatic Ductal Adenocarcinoma (PDAC), an aggressive can-
cer, interacts with stromal cells to produce a highly inﬂammatory
tumor microenvironment in order to promotes tumor growth and
invasiveness. TLRs mediate interactions between environmental
stimuli and innate immunity and trigger proinﬂammatory signal-
ing cascades. It is likely that TLR activation, either directly or
indirectly via stromal cell activation, promotes an aggressive
phenotype in the at-risk epithelial cells, which, in turn, induces
oncogene-induced senescence (OIS). The ligation of TLRs causes
derangements in several tumor suppressor proteins (such as p16,
p21, p27, p53 and pRb), STAT3 activation and interfaces with
Notch, NF-jB and MAP kinase pathways [60]. These effects seem
to be due to stromal cells, since chimeric mice with Tlr4/ or
Tlr7/ bone marrows, were partially protected from pancreatic
carcinogenesis [60,61].
Zambirinis and colleagues explored the effects of
TLR-MyD88/TRIF signaling on pancreatic carcinogenesis in
p48Cre; LslKrasG12D pancreatic cancer mouse model. Mice treated
with either TLR3, TLR4 or TLR7 agonists exhibited a dramatic
acceleration of pancreatic cancer progression, characterized by
more advanced pre-invasive (PanIN) lesions and a higher number
of invasive foci, as well as increased ﬁbrosis and augmented
immune inﬁltrate [62].
The inhibition of MYD88 in DCs leads CD4+ T cells toward a TH2
proﬁle and to an acceleration of cancer progression by perpetuat-
ing inﬂammation [61]. Similarly, the activation of STAT3 and the
upregulation of NOTCH receptors and ligands occur in both the
epithelial and the stromal component of PDAC and contribute via
NFjB and MAPK to the aggressive tumor phenotype induced by
TLR7 activation [63].
Supporting data came from Ochi et al. They revealed the
primary role for DCs in pancreatic carcinogenesis and showed that
the blockade of TLR4 signaling, via TRIF, is protective against
pancreatic cancer. In the same study, they showed that MyD88
inhibition, by augmenting the DC-TH2 axis, can exacerbate pancreatic
inﬂammation and neoplastic transformation [61].
LPS-related TLR4 signaling could be a triggering factor in the
initiation and progression of pancreatic cancer [64,65], directly
modulating the transition from pancreatic inﬂammation toFig. 3. Epithelial–mesenchymal transition (EMT) is proposed to play a role in pancreatic c
cells lose their cell polarity and gain migratory and invasive properties to become mese
Carcinoma cells in primary tumor lose their E-cadherin-mediated cell–cell adhesion and b
the bloodstream through intravasation.
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[61,66]. In PDAC tissue, TLR4 is expressed and its levels have been
shown to correlate with tumor size, lymph node involvement,
venous invasion, and pathological stage [67]. Moreover, TLR4
expression in pancreatic cancer cells is up-regulated via HIF-1a
in response to hypoxic stress and underscore the crucial role of
HIF-1a-induced TLR4 in PDAC tumor growth [68]. Patients with
overexpressed TLR4 or overexpressed HIF-1a had a signiﬁcantly
shorter survival period compared to the patients with normal
expression, while longer survival (p = 0.014) was reported among
patients with neither TLR4 nor HIF-1a over expression [69].
The epithelial–mesenchymal transition (EMT) in pancreatic
cancer promoted by M2-polarized tumor-associated macrophages
partially involves the TLR4/IL-10 signaling pathway (Fig. 3).
Indeed, the application of TLR4 siRNA and neutralizing antibodies
against TLR4 and IL-10 markedly inhibited the reduction of epithe-
lial marker E-cadherin and the upregulation of mesenchymal
markers snail and vimentin induced by TLR4 [70].
Therapeutic perspectives
TLR2 seems to be expressed in over 70% of pancreatic tumors
but not in normal pancreas tissue. The potential use of synthetic
TLR2 agonists for the enhancement of cancer immunotherapy is
an active area of research. Three mechanisms are involved in the
antitumor activity of TLR2: induction of apoptosis in
TLR2-positive tumors, enhancement of the innate and T-cell
immunity, and improvement of cytotoxic antibody function.
Huynh and colleagues demonstrated the PDAC speciﬁc retention
of the ﬂuorescently labeled compound IRDye800CW-Mpr-,
in vivo, using mice bearing TLR2 expressing xenografts [71]. The
intraoperative use for increasing the detection of negative resec-
tion margins should be prospectively investigated.
A phase I/II trial examined the TLR 2/6 agonist MALP-2 in com-
bination with gemcitabine in patients with locally advanced
PDACs. Ten patients were injected intratumorally during surgery
with 20–30 mg of MALP-2 followed by postoperative chemother-
apy. The median survival was 9.3 months, with two patients still
alive after 31 months [72].
Immune responses are impaired in pancreatic cancer patients. A
promising strategy for interfering with tumor immune evasion canancer invasion. In response to inﬂammation, mediated by TLR4/IL-10 axis, epithelial
nchymal cells. Loss of E-cadherin is considered to be a fundamental event in EMT.
reak through the basement membrane with increased invasive properties, and enter
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stimulatory complexes (ISCOM) and TLR agonists. Jacobs et al.
investigated the efﬁcacy of an ISCOM vaccine alone or in combina-
tion with the TLR9 agonist CpG in a murine pancreatic carcinoma
model. Unfortunately, ISCOM vaccine, alone, did not affect tumor
growth, but its combination with CpG enhanced cytotoxic T
lymphocyte responses and induced regression of pancreatic
tumors in a CD8+ T cell-dependent manner [73].
Other data on the potential role of TLR9 in cancer were showed
by Rosa et al. A TLR9 agonist immunomodulatory oligonucleotide
(IMO) alone or in combination with cetuximab was investigated
in subcutaneous colon and orthotopic pancreatic cancer models
harboring K-Ras mutations and resistance to EGFR inhibitors.
They reported that IMO markedly inhibited growth of K-Ras
mutant colon and pancreatic cancers in vitro and in nude mice
and cooperated with cetuximab via multiple mechanisms of action,
suggesting for its use in cetuximab-resistant colorectal and pancre-
atic cancers [74].
Zhou et al. evaluated whether 6-shogaol, a hydroxycinnamic
acid derivative extracted from ginger, could suppress pancreatic
cancer progression and potentiate response to gemcitabine treat-
ment in vitro and in vivo. They showed that 6-shogaol prevented
the activation of TLR4/NF-jB signaling and suppressed key cell
survival regulators including cyclooxygenase 2 (COX-2), cyclinD1,
survivin, cIAP-1, XIAP, Bcl-2, and MMP-9. In addition, 6-shogaol
inhibited the growth of human pancreatic tumors and sensitized
them to gemcitabine by suppressing of TLR4/NF-jB-mediated
inﬂammatory pathways linked to tumorigenesis [75].
MicroRNAs (miRNAs) are a class of highly conserved non-coding
small RNAs. It’s been shown that several miRNAs, including
miR-301a, can affect the expression of different proteins in the
NF-jB pathway in immune cells, thus affecting the production of
inﬂammatory mediators such as IL-1b and TNFa. miR-301a is
speciﬁcally over-expressed in a number of cancers, including
PDAC [76].
miR-301a down-regulates its target gene, NF-jB repressing fac-
tor (NKRF), by enhancing NF-jB activity. The downregulation of
miR-301a expression leads to a suppressed TLR-dependent innate
immune response by reducing macrophage COX-2 and IL-6 expres-
sion. These data suggest that miR-301a inhibition or NKRF
up-regulation can reduce NF-jB target gene expression and tumor
growth, representing a potential therapeutic approach in patients
with PDAC [77].Conclusions
Pancreatic inﬂammation, diabetes and tumor progression
involves TLR-mediated irregular and uninhibited production of
proinﬂammatory cytokines, chemokines, and also immunosup-
pressive cytokines, suggesting that the discovery of TLR antago-
nists might be an ideal therapeutic strategy. However, TLR
antagonists could pose the risk to compromise host immunity,
mostly in cancer patients. Although the use of TLR agonists and
antagonists may provide a beneﬁt in patients with pancreatic
cancer and disease, interest is centered on the potential to comple-
ment exist ing modes of therapy with radiation, monoclonal
antibodies or cyto toxic drugs.
In summary, TLRs represent promising therapeutic targets in
patients with AP, diabetes and PDAC, although further research
and elucidation of involved mechanisms are warranted in order
to explore their potential future clinical implications.Founding
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